NURS 572 Exam 3 Summary Table Complete Study Guide & Practice Questions 2026–2027

NURS 572 Exam 3 Summary Table | Complete
Study Guide & Practice Questions 2026–2027
1. Dopaminergics: MechanismofAction: i i i




- Increasing dopamine (DA)synthesis inthe striatum i i i i i i




- Undergoes uptake into dopaminergic nerve terminals and converted into dopamine
i i i i i i i i i




- Carbidopa inhibits decarboxylation of levodopa in the intestine and peripheral tissues
i i i i i i i i i i




Therapeutic Uses: i




Parkinsondisease(PD) i i




Adverse Ettects: i




- Ettectsaredosedependent i i i




- Nauseaandvomiting i i




- Dyskinesias
- Postural
- Hypertension
- Psychosis

Nursing Implications: i




Informpatientsthatbenefitsofdrugmaybedelayedforweekstomonths
i i i i i i i i i i i i




Additional information: i




- Symptomaticrelief,nocure i i i




- Full therapeutic responses take months to develop
i i i i i i




- Acute loss of ettect occurs
i i i i




2. Dopaminergics - (medications): -Donepezil(Aricept) i i i i i




- Carbidopa/Levodopa (Sinemet) i




3. Centrally-acting Anticholinergics: MechanismofAction: i i i i




- Blocks muscarinic, cholinergic receptors in the striatum
i i i i i i




- Also blocks cholinergic receptors inthe periphery
i i i i i i




- Improves balancebetween dopamineand acetylcholine
i i i i i




Therapeutic Uses: i




Parkinson disease i





i i

,Adverse Ettects:
i




- Peripheral ettects: i




a. Drymouth
i




b. Blurredvision i




c. Urinary retention i




d. Tachycardia
- Constipation

Nursing Implications:
i




Educate patient to not discontinue drug abruptly
i i i i i i




Additional information: i




Low doses initially, dose gradually increased
i i i i i




4. Centrally-acting Anticholinergics - (medications): -Atropine(AtroPen) i i i i i i




- Benztropine Mesylate (Cogentin) i i




5. ReversibleCholinesteraseInhibitors(Anticholinesterases):MechanismofAction: i i i i i i




- Reversibly binds to cholinesterase preventing the degradation of acetylcholine by (acetyl)cholinesterase centrally
i i i i i i i i i i i




- Resultsinincreasedamountofacetylcholineavailabletoactivatereceptors
i i i i i i i i i




- Enhanced transmission in central cholinergic neurons that have not yet been destroyed
i i i i i i i i i i i




Therapeutic Uses: i




Alzheimer's disease (AD) i i




Adverse Ettects:
i




- Cholinergic ettects: i




a. Nausea, vomiting i




b. Dyspepsia
c. Diarrhea
d. Dizziness
- Headache

Nursing Implications: Medication
i i




adherence is crucial
i i i





i i

, Additional information: i




- Slowslossofmemoryandcognition
i i i i i




- Prolongsindependentfunction i i




- Nocure i




6. Reversible Cholinesterase Inhibitors (Anticholinesterases) - (Medications): - i i i i i i




Donepezil(Aricept)
i i




7. N-methyl-D-aspartate(NMDA)ReceptorAntagonists:MechanismofAction: i i i i i i




Modulates the ettects of glutamate at NMDA receptor
i i i i i i i i




Therapeutic Uses: i




Alzheimer's disease i




Adverse Ettects: i




- Dizziness
- Headache
- Confusion
- Constipation

Nursing Implications: i




Medicationadherence is crucial i i i




Additional information: i




Slows decline in function
i i i




8. N-methyl-D-aspartate (NMDA) Receptor Antagonists - (Medications): -Meman-tine i i i i i i i




(Namenda)
i




9. Immunomodulators: MechanismofAction: i i i




- Manufactured by DNA recombinant therapy i i i i




- Enhances naturally occurring interferon i i i




- Interferon beta is a glycoprotein that inhibits the migration of proinflammatory leukocytes across the BBB and suppresses
i i i i i i i i i i i i i i i i




T-helper cell activity
i i i




Therapeutic Uses: i





i i